A review of health utilities using the EQ-5D in studies of cardiovascular disease - PubMed (original) (raw)

Review

A review of health utilities using the EQ-5D in studies of cardiovascular disease

Matthew T D Dyer et al. Health Qual Life Outcomes. 2010.

Abstract

Background: The EQ-5D has been extensively used to assess patient utility in trials of new treatments within the cardiovascular field. The aims of this study were to review evidence of the validity and reliability of the EQ-5D, and to summarise utility scores based on the use of the EQ-5D in clinical trials and in studies of patients with cardiovascular disease.

Methods: A structured literature search was conducted using keywords related to cardiovascular disease and EQ-5D. Original research studies of patients with cardiovascular disease that reported EQ-5D results and its measurement properties were included.

Results: Of 147 identified papers, 66 met the selection criteria, with 10 studies reporting evidence on validity or reliability and 60 reporting EQ-5D responses (VAS or self-classification). Mean EQ-5D index-based scores ranged from 0.24 (SD 0.39) to 0.90 (SD 0.16), while VAS scores ranged from 37 (SD 21) to 89 (no SD reported). Stratification of EQ-5D index scores by disease severity revealed that scores decreased from a mean of 0.78 (SD 0.18) to 0.51 (SD 0.21) for mild to severe disease in heart failure patients and from 0.80 (SD 0.05) to 0.45 (SD 0.22) for mild to severe disease in angina patients.

Conclusions: The published evidence generally supports the validity and reliability of the EQ-5D as an outcome measure within the cardiovascular area. This review provides utility estimates across a range of cardiovascular subgroups and treatments that may be useful for future modelling of utilities and QALYs in economic evaluations within the cardiovascular area.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Summary of literature search.

Figure 2

Figure 2

EQ-5D Index Mean scores for Heart Failure patients - Stratified by baseline disease severity (NYHA class).

Figure 3

Figure 3

EQ-5D Index Mean scores for IHD patients - Stratified by baseline disease severity (CCS class).

Figure 4

Figure 4

Distribution of Scores for Mobility Dimension of EQ-5D.

Figure 5

Figure 5

Distribution of Scores for Self-Care Dimension of EQ-5D.

Figure 6

Figure 6

Distribution of Scores for Usual Activities Dimension of EQ-5D.

Figure 7

Figure 7

Distribution of Scores for Pain/Discomfort Dimension of EQ-5D.

Figure 8

Figure 8

Distribution of Scores for Anxiety/Depression Dimension of EQ-5D.

Similar articles

Cited by

References

    1. World Health Organisation. The World Health Report 2003: Shaping the Future. Geneva. 2003.
    1. Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J. 2006;27:1610–1619. doi: 10.1093/eurheartj/ehi733. - DOI - PubMed
    1. Swenson JR, Clinch JJ. Assessment of quality of life in patients with cardiac disease - the role of psychosomatic medicine. J Psychosom Res. 2000;48:405–415. doi: 10.1016/S0022-3999(99)00092-6. - DOI - PubMed
    1. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9. Boston, Mass.: Little, Brown & Co; 1994.
    1. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol. 2002;18:439–442. - PubMed

Publication types

MeSH terms

LinkOut - more resources